Registration of Veterinary Pharmaceuticals in China: Key Pathways and Recent Updates for 2026

China is one of the world’s largest animal health markets, driven by intensive livestock production, expanding aquaculture, and a fast-growing companion animal sector. However, veterinary pharmaceuticals must undergo a structured regulatory approval process before they can be manufactured, imported, or sold. With recent regulatory refinements continuing through 2026, understanding the current framework is essential for successful market entry.

Regulatory Authority and Framework

Veterinary pharmaceutical registration in China is overseen by the Ministry of Agriculture and Rural Affairs (MARA). The regulatory system is based primarily on the Regulations on the Administration of Veterinary Drugs and related implementation measures. These rules ensure that veterinary medicines meet standards for safety, efficacy, and quality while protecting food safety, public health, and animal welfare.

Products requiring registration include vaccines, chemical drugs, biologics, herbal veterinary medicines, diagnostic agents, and some medicated feed additives.

Recent Updates (2024–2026)

Improved dossier standards (2025):
Regulators introduced stricter expectations for documentation completeness, supporting data reliability, and overall application quality. This aims to improve transparency and reduce approval delays.

Expanded product scope:
Some diagnostic and companion animal health products have been clarified as falling under veterinary drug regulation, reflecting growth in China’s pet healthcare sector.

Broader pharmaceutical regulatory reform influence (2026):
China continues to modernize drug approval systems, including accelerated pathways such as priority review. Although focused mainly on human medicines, these reforms signal a trend toward faster, more efficient regulatory processes that may influence veterinary approvals.

Import supervision adjustments (2025):
Changes to customs oversight have streamlined certain import procedures while maintaining regulatory safety controls.

Key Challenges and Opportunities

The Chinese regulatory system remains rigorous. Common challenges include detailed documentation requirements, evolving regulatory expectations, and the need for local regulatory expertise. However, opportunities are significant due to:

• Rapid growth in pet healthcare demand
• Continued expansion of livestock production
• Increased focus on food safety and disease control
• Government support for pharmaceutical innovation

Companies that engage local expertise early and align development strategies with Chinese regulatory expectations often experience smoother approvals.

Resources Used

• Ministry of Agriculture and Rural Affairs (China) veterinary drug regulations and guidance documents
• China Institute of Veterinary Drug Control publications
• Regulatory consultancy updates (e.g., CIRS Group, Cisema regulatory briefings)
• International trade and regulatory news reports (including Reuters coverage of import supervision changes)
• Industry regulatory summaries on veterinary pharmaceutical compliance in China

Published on Mar 16, 2026 by Ella Thomas